Hill M - Search Results

1

Pridopidine, a clinic-ready compound, reduces 3,4-dihydroxyphenylalanine-induced dyskinesia in Parkinsonian macaques.

Johnston TH, Geva M, Steiner L, Orbach A, Papapetropoulos S, Savola JM, Reynolds IJ, Ravenscroft P, Hill M, Fox SH, Brotchie JM, Laufer R, Hayden MR. Johnston TH, et al. Among authors: hill m. Mov Disord. 2019 May;34(5):708-716. doi: 10.1002/mds.27565. Epub 2018 Dec 21. Mov Disord. 2019. PMID: 30575996

2

TC-8831, a nicotinic acetylcholine receptor agonist, reduces L-DOPA-induced dyskinesia in the MPTP macaque.

Johnston TH, Huot P, Fox SH, Koprich JB, Szeliga KT, James JW, Graef JD, Letchworth SR, Jordan KG, Hill MP, Brotchie JM. Johnston TH, et al. Among authors: hill mp. Neuropharmacology. 2013 Oct;73:337-47. doi: 10.1016/j.neuropharm.2013.06.005. Epub 2013 Jun 14. Neuropharmacology. 2013. PMID: 23770260

3

Pharmacokinetic/Pharmacodynamic Correlation Analysis of Amantadine for Levodopa-Induced Dyskinesia.

Brigham EF, Johnston TH, Brown C, Holt JDS, Fox SH, Hill MP, Howson PA, Brotchie JM, Nguyen JT. Brigham EF, et al. Among authors: hill mp. J Pharmacol Exp Ther. 2018 Nov;367(2):373-381. doi: 10.1124/jpet.118.247650. Epub 2018 Aug 7. J Pharmacol Exp Ther. 2018. PMID: 30087157

4

Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease.

Fox SH, Henry B, Hill M, Crossman A, Brotchie J. Fox SH, et al. Among authors: hill m. Mov Disord. 2002 Nov;17(6):1180-7. doi: 10.1002/mds.10289. Mov Disord. 2002. PMID: 12465055

5

Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease.

Savola JM, Hill M, Engstrom M, Merivuori H, Wurster S, McGuire SG, Fox SH, Crossman AR, Brotchie JM. Savola JM, et al. Among authors: hill m. Mov Disord. 2003 Aug;18(8):872-83. doi: 10.1002/mds.10464. Mov Disord. 2003. PMID: 12889076

6

NYX-458 Improves Cognitive Performance in a Primate Parkinson's Disease Model.

Barth AL, Schneider JS, Johnston TH, Hill MP, Brotchie JM, Moskal JR, Cearley CN. Barth AL, et al. Among authors: hill mp. Mov Disord. 2020 Apr;35(4):640-649. doi: 10.1002/mds.27962. Epub 2020 Jan 22. Mov Disord. 2020. PMID: 31967361

7

Use of catechol-O-methyltransferase inhibition to minimize L-3,4-dihydroxyphenylalanine-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque.

Huot P, Johnston TH, Snoeren T, Koprich JB, Hill MP, Fox SH, Brotchie JM. Huot P, et al. Among authors: hill mp. Eur J Neurosci. 2013 Mar;37(5):831-8. doi: 10.1111/ejn.12093. Epub 2013 Jan 3. Eur J Neurosci. 2013. PMID: 23281915

8

Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset.

Hill MP, Bezard E, McGuire SG, Crossman AR, Brotchie JM, Michel A, Grimée R, Klitgaard H. Hill MP, et al. Mov Disord. 2003 Nov;18(11):1301-5. doi: 10.1002/mds.10542. Mov Disord. 2003. PMID: 14639671

9

Antiparkinsonian effects of the novel D3/D2 dopamine receptor agonist, S32504, in MPTP-lesioned marmosets: Mediation by D2, not D3, dopamine receptors.

Hill MP, Ravenscroft P, McGuire SG, Brotchie JM, Crossman AR, Rochat C, Millan MJ. Hill MP, et al. Mov Disord. 2006 Dec;21(12):2090-5. doi: 10.1002/mds.21106. Mov Disord. 2006. PMID: 16991143

10

Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease.

Kobylecki C, Hill MP, Crossman AR, Ravenscroft P. Kobylecki C, et al. Mov Disord. 2011 Nov;26(13):2354-63. doi: 10.1002/mds.23867. Epub 2011 Sep 23. Mov Disord. 2011. PMID: 21953539

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

5,949 results

Search Page

Filters